Three Year Results in Patients with LAD Lesions Treated with DynamX Bioadaptor Compared to a Contemporary DES: From the BIOADAPTOR-RCT Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Elixir; Boston Scientific Corporation; Terumo Medical Corporation; Medtronic; Biotronik</li><li>Grant Support/Research Contract - Shockwave Medical</li></ul>